Korean J Schizophr Res.  2014 Oct;17(2):72-79. 10.16946/kjsr.2014.17.2.72.

Correlation of Lifetime Symptom Dimensions with Cognitive Function and Other Clinical Characteristics in Schizophrenia Patients

Affiliations
  • 1Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. hongks@skku.edu
  • 2Center for Clinical Research, Samsung Biomedical Research Institute, Seoul, Korea.
  • 3Department of Biostatistics, Boramae Medical Center, Seoul, Korea.
  • 4Department of Statistics, Seoul National University, Seoul, Korea.

Abstract


OBJECTIVES
Considering large diversity of clinical presentation of schizophrenia, it is important to identify valid clinical subtypes or dimensions that might have homogeneous biological underpinning. The current study aimed to explore lifetime symptom-based dimensional phenotypes in patients with chronic schizophrenia, and to investigate their correlation with cognitive functions and other clinical characteristics.
METHODS
Lifetime-based symptoms and additional clinical variables were measured using the Diagnostic Interview for Genetic Studies and the Schedule for the Deficit Syndrome in 315 clinically stable patients with chronic schizophrenia. Through principal components factor analysis, eight dimensional phenotypes were obtained. Comprehensive neuropsychological tests were administered for 103 out of 315 patients, and domain scores were calculated for cognitive domains defined in the MATRICS consensus battery.
RESULTS
'Non-paranoid delusion factor' including delusions of grandiose or religious nature, showed significant negative correlation with processing speed, working memory, attention/vigilance, and general cognitive ability, and positive correlation with intra-individual variability. 'Negative symptom factor' showed significant negative correlation only with general cognitive ability. Those two factors were also negatively correlated with function levels measured by Global Assessment Scale (GAS), and associated with poor treatment responses.
CONCLUSION
Symptom-based dimensional phenotypes of schizophrenia measured on a lifetime basis showed discriminative correlation with cognitive function domains, global functioning level, and overall treatment responses, indicating their possibility as valid phenotype axes of schizophrenia having homogeneous biologic basis.

Keyword

Schizophrenia; Symptom dimensions; Cognition

MeSH Terms

Appointments and Schedules
Cognition
Consensus
Delusions
Humans
Memory, Short-Term
Neuropsychological Tests
Phenotype
Schizophrenia*

Reference

References

1. Andreasen NC, Flaum M. Schizophrenia: the characteristic symptoms. Schizophr Bull. 1991; 17:27–49.
Article
2. American Psychiatric Association. Diagnostic And Statistical Manual Of Mental Disorders. 4th ed. (Text Revision).Washington, DC: American Psychiatric Press;2000.
3. American Psychiatric Association. Diagnostic And Statistical Manual of Mental Disorders. 5th ed.Washington, DC: American Psychiatric Press;2013.
4. Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013; 150:3–10.
Article
5. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008; 102:1–18.
Article
6. Bilder RM, Mukherjee S, Rieder RO, Pandurangi AK. Symptomatic and neuropsychological components of defect states. Schizophr Bull. 1985; 11:409–419.
Article
7. Liddle PF. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br J Psychiatry. 1987; 151:145–151.
8. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia. Methods, meanings, and mechanisms. Arch Gen Psychiatry. 1995; 52:341–351.
9. Peralta V, de Leon J, Cuesta MJ. Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy. Br J Psychiatry. 1992; 161:335–343.
10. Fanous AH, van den Oord EJ, Riley BP, Aggen SH, Neale MC, O'Neill FA, et al. Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry. 2005; 162:1824–1832.
11. Rietkerk T, Boks MP, Sommer IE, Liddle PF, Ophoff RA, Kahn RS. The genetics of symptom dimensions of schizophrenia: review and metaanalysis. Schizophr Res. 2008; 102:197–205.
Article
12. Vassos E, Sham PC, Cai G, Deng H, Liu X, Sun X, et al. Correlation and familial aggregation of dimensions of psychosis in affected sibling pairs from China. Br J Psychiatry. 2008; 193:305–310.
13. Wickham H, Walsh C, Asherson P, Taylor C, Sigmundson T, Gill M, et al. Familiality of symptom dimensions in schizophrenia. Schizophr Res. 2001; 47:223–232.
Article
14. McGrath JA, Avramopoulos D, Lasseter VK, Wolyniec PS, Fallin MD, Liang KY, et al. Familiality of novel factorial dimensions of schizophrenia. Arch Gen Psychiatry. 2009; 66:591–600.
Article
15. Ryu S, Won HH, Oh S, Kim JW, Park T, Cho EY, et al. Genomewide linkage scan of quantitative traits representing symptom dimensions in multiplex schizophrenia families. Psychiatry Res. 2013; 210:756–760.
Article
16. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000; 14:1–21.
Article
17. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998; 12:426–445.
Article
18. Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005; 31:5–19.
Article
19. Bora E, Murray RM. Meta-analysis of Cognitive Deficits in Ultrahigh Risk to Psychosis and First-Episode Psychosis: Do the Cognitive Deficits Progress Over, or After, the Onset of Psychosis? Schizophr Bull. 2014; 40:744–755.
Article
20. Cornblatt BA, Lenzenweger MF, Dworkin RH, Erlenmeyer-Kimling L. Childhood attentional dysfunctions predict social deficits in unaffected adults at risk for schizophrenia. Br J Psychiatry Suppl. 2006. 59–64.
Article
21. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry. 1999; 156:1328–1335.
22. Nopoulos P, Flashman L, Flaum M, Arndt S, Andreasen N. Stability of cognitive functioning early in the course of schizophrenia. Schizophr Res. 1994; 14:29–37.
Article
23. Finkelstein JR, Cannon TD, Gur RE, Gur RC, Moberg P. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings. J Abnorm Psychol. 1997; 106:203–212.
Article
24. Gur RE, Nimgaonkar VL, Almasy L, Calkins ME, Ragland JD, Pogue-Geile MF, et al. Neurocognitive endophenotypes in a multiplex multigenerational family study of schizophrenia. Am J Psychiatry. 2007; 164:813–819.
Article
25. Snitz BE, Macdonald AW 3rd, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull. 2006; 32:179–194.
Article
26. Strauss ME. Relations of symptoms to cognitive deficits in schizophrenia. Schizophr Bull. 1993; 19:215–231.
Article
27. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000; 157:549–559.
Article
28. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry. 1999; 56:749–754.
29. Hughes C, Kumari V, Soni W, Das M, Binneman B, Drozd S, et al. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res. 2003; 59:137–146.
Article
30. Gold S, Arndt S, Nopoulos P, O'Leary DS, Andreasen NC. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry. 1999; 156:1342–1348.
31. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004; 56:301–307.
Article
32. Green MF, Nuechterlein KH. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res. 2004; 72:1–3.
Article
33. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004; 72:29–39.
Article
34. Noh J, Kim JH, Hong KS, Kim N, Nam HJ, Lee D, et al. Factor structure of the neurocognitive tests: an application of the confirmative factor analysis in stabilized schizophrenia patients. J Korean Med Sci. 2010; 25:276–282.
Article
35. Joo EJ, Joo YH, Hong JP, Hwang S, Maeng SJ, Han JH, et al. Korean version of the diagnostic interview for genetic studies: Validity and reliability. Compr Psychiatry. 2004; 45:225–229.
Article
36. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989; 30:119–123.
Article
37. Guy W. Clinical global impression scale. The ECDEU Assessment Manual for Psychopharmacology-Revised. Volume DHEW Publ No ADM 76. 1976; 338:218–222.
38. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976; 33:766–771.
39. Baek JH, Kim JS, Ryu S, Oh S, Noh J, Lee WK, et al. Association of genetic variations in DTNBP1 with cognitive function in schizophrenia patients and healthy subjects. Am J Med Genet B Neuropsychiatr Genet. 2012; 159B:841–849.
Article
40. Holtzer R, Verghese J, Wang C, Hall CB, Lipton RB. Within-person across-neuropsychological test variability and incident dementia. JAMA. 2008; 300:823–830.
Article
41. Carlsson R, Nyman H, Ganse G, Cullberg J. Neuropsychological functions predict 1- and 3-year outcome in first-episode psychosis. Acta Psychiatr Scand. 2006; 113:102–111.
Article
42. Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocog-nition and functional outcome in schizophrenia: a metaanalysis. Schizophr Res. 2009; 113:189–199.
Article
43. Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW. Neuropsychology of the deficit syndrome: new data and metaanalysis of findings to date. Schizophr Bull. 2007; 33:1201–1212.
Article
44. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neu-rocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005; 162:495–506.
Article
45. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012; 137:147–150.
Article
46. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondefi-cit forms of schizophrenia: the concept. Am J Psychiatry. 1988; 145:578–583.
47. Dunayevich E, Keck PE Jr. Prevalence and description of psychotic features in bipolar mania. Curr Psychiatry Rep. 2000; 2:286–290.
Article
48. Arai M, Yamada K, Toyota T, Obata N, Haga S, Yoshida Y, et al. Association between polymorphisms in the promoter region of the sialyltransferase 8B (SIAT8B) gene and schizophrenia. Biol Psychiatry. 2006; 59:652–659.
Article
49. Vazza G, Bertolin C, Scudellaro E, Vettori A, Boaretto F, Rampinelli S, et al. Genomewide scan supports the existence of a susceptibility locus for schizophrenia and bipolar disorder on chromosome 15q26. Mol Psychiatry. 2007; 12:87–93.
Article
50. Taylor MA. Schneiderian first-rank symptoms and clinical prognostic features in schizophrenia. Arch Gen Psychiatry. 1972; 26:64–67.
Article
51. Nordgaard J, Arnfred SM, Handest P, Parnas J. The diagnostic status of first-rank symptoms. Schizophr Bull. 2008; 34:137–154.
Article
52. Lewandowski KE, DePaola J, Camsari GB, Cohen BM, Ongur D. Tactile, olfactory, and gustatory hallucinations in psychotic disorders: a descriptive study. Ann Acad Med Singapore. 2009; 38:383–385.
53. Yamada N, Nakajima S, Noguchi T. Age at onset of delusional disorder is dependent on the delusional theme. Acta Psychiatr Scand. 1998; 97:122–124.
Article
Full Text Links
  • KJSR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr